BridgeBio's Infigratinib Succeeds in Phase 3 Trial for Achondroplasia Dwarfism on February 13, 2026 Achondroplasia BridgeBio Dwarfism height velocity infigratinib Phase 3 +
FDA Delays Decision on Ascendis' Dwarfism Drug by Three Months on November 26, 2025 Achondroplasia Approved Ascendis Pharma CNP gene Deferred Dwarfism navepegritide PDUFA post-marketing requirement TransCon United States Food and Drug Administration +